Risk factors
Precision Biosciences (DTIL) risk factors
Item 1A of every Precision Biosciences Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors73 risks5 new21 dropped18 reworded
Precision BioSciences added regulatory risks covering UK clinical trials, US orphan drug designations, FDA Fast Track, and EU Health Technology Assessments.
Filed Mar 12, 2026 - FY2024 10-K risk factors89 risks
Precision Biosciences faces substantial risks related to its ongoing operating losses, accumulated deficit of $482.5 million, and heavy reliance on the unproven ARCUS genome editing technology.
Filed Mar 26, 2025